Update: In March 2019, we posted on the “MHRA’s extensive no-deal guidance updates for pharma and medtech”. Following on from the MHRA’s published guidance on ‘grandfathering’ and managing the lifecycle changes of medicinal products (see here), the MHRA has released an update in regards to the time period companies must…

Update on Brexit threat: gaps in the medicines stored, and stockpiling itself causing disruption Update: We have been posting regularly on medicines supplies as part of the MHRA’s guidance on minimising the risks and dangers of medicines and medical supply stockpiling in the event of a no-deal Brexit and the…

This post reproduces a client alert, available here. The current situation surrounding the UK’s departure from the EU remains uncertain. At present, following the European Council’s decision to grant the UK’s request for an extension for time, the UK is legally due to leave the EU on 12 April 2019.…

Update: in January we posted on the “Serious Shortage Protocol” (SSP) as a part of government plans aimed at minimising any disruption to the supply of medical devices and prescription medication in the event of a no-deal Brexit.  As of 9 February 2019 the SSPs have come into force through…